We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Cepheid Obtains CE Marking for Same-Day Diagnostic Equipment

By LabMedica International staff writers
Posted on 30 May 2012
Cepheid (Sunnyvale, CA, USA), a molecular diagnostics company that develops and manufactures molecular systems and tests, announced that both Xpert CT/NG and Xpert CT have received CE marking, enabling the products to be shipped to Europe immediately.

The products, which run on Cepheid's GeneXpert System, are in vitro (IV) molecular diagnostic tests that detect and differentiate Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG), two sexually transmitted infections (STIs).

Image: The GeneXpert system, a single-use cartridge system designed for sample preparation, extraction, and elution through amplification, with minimal hands-on time during the process (Photo courtesy of Cepheid).
Image: The GeneXpert system, a single-use cartridge system designed for sample preparation, extraction, and elution through amplification, with minimal hands-on time during the process (Photo courtesy of Cepheid).

Gonorrhoeae and chlamydia are easily treated once diagnosed and managed. However, according to the European Centers for Disease Control and Prevention (ECDC), the rate of infection for both infections has increased during the last decade.

Current testing materials for both gonorrhoeae and chlamydia are slow and problematic, oftentimes requiring additional tests to confirm diagnosis. The delays and inaccuracies in testing have hampered communication between patients and doctors, leaving patients unaware of their infections and unable to procure treatment.

Cepheid’s new products provide diagnostic results in less than 90 minutes, enabling same-day patient consultation and treatment options.

"We are bringing to market a true next-generation molecular diagnostic product for detection of CT/NG a test designed from the ground up to provide unprecedented accuracy, ease of use, and results availability," said John Bishop, CEO, Cepheid. "We expect these innovative products to deliver new levels of confidence to clinicians making same-day decisions in consulting with, and treating, their patients the critical first step in effectively managing these diseases."

Xpert CT/NG will be immediately available as a CE-marked product and is expected to become available in the United States in late 2012.


Related Links:

Cepheid


Gold Member
Cardiovascular Risk Test
Metabolic Syndrome Array I & II
Portable Electronic Pipette
Mini 96
Hemodynamic System Monitor
OptoMonitor
ESR Analyzer
TEST1 2.0

Latest Technology News

Taste-Based Influenza Test Could Replace Nasal Swabs with Chewing Gum
30 May 2012  |   Technology

3D Micro-Printed Sensors to Advance On-Chip Biosensing for Early Disease Detection
30 May 2012  |   Technology

Hybrid Pipette Combines Manual Control with Fast Electronic Aliquoting
30 May 2012  |   Technology